

Presentation	Supplier Name	Market Segment	Pneumococcal Conjugate Vaccine																
			2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	
Pneumococcal Conjugate vaccine, 13 valent, single dose vial presentation	Pfizer (USA)	AMC/Gavi 73*			\$7.0000	\$7.0000	\$7.0000	\$7.0000/ \$3.5000- \$3.4000	\$7.0000/ \$3.3000	\$7.0000/ \$3.3000	\$7.0000/ \$3.3000	\$3.3000	\$3.3000	\$3.3000	\$3.3000	\$3.3000	\$3.3000	\$3.3000	
		MICs												\$15.6700- \$25.0000	\$15.6700- \$25.0000	\$15.6700- \$25.0000	\$15.6700- \$25.0000	\$14.7300- \$45.0000	
Pneumococcal Conjugate vaccine, 13 valent, four dose vial presentation	Pfizer (USA)	AMC/Gavi 73*										\$3.0500	\$2.9500	\$2.9000	\$2.9000	\$2.9000	\$2.9000	\$2.9000	\$2.7500
		MICs																	\$15.4600
		Humanitarian											\$3.0500	\$2.9500	\$2.9000	\$2.9000	\$2.9000	\$2.9000	\$2.9000
Pneumococcal Conjugate vaccine, 10 valent, two dose vial presentation	GlaxoSmithKline Biologicals (Belgium)	AMC/Gavi 73*			\$7.0000	\$7.0000	\$7.0000	\$7.0000/ \$3.5000- \$3.4000	\$7.0000/ \$3.5000- \$3.4000	\$7.0000/ \$3.5000- \$3.4000	\$7.0000/ \$3.5000- \$3.4000	\$7.0000/ \$3.0500	\$3.0500	\$3.0500					
Pneumococcal Conjugate vaccine, 10 valent, four dose vial presentation	GlaxoSmithKline Biologicals (Belgium)	AMC/Gavi 73*											\$3.0500	\$3.0500	\$3.0500	\$3.0500	\$3.0500	\$3.0500	\$2.9000
		MICs												\$10.9000	\$10.9000				
		Humanitarian											\$3.0500	\$3.0500	\$3.0500	\$3.0500	\$3.0500	\$3.0500	\$2.9000
Pneumococcal Conjugate vaccine, 10 valent, five dose vial presentation	Serum Institute of India	AMC/Gavi 73*													\$7.0000/ \$2.0000	\$7.0000/ \$2.0000	\$7.0000/ \$2.0000	\$7.0000/ \$1.5000	
		MICs													\$2.9000- \$4.0000	\$2.9000- \$4.0000	\$2.9000- \$4.0000	\$2.9000- \$4.0000	
Pneumococcal Conjugate vaccine, 10 valent, one dose vial presentation	Serum Institute of India	AMC/Gavi 73*													\$2.9000	\$2.9000	\$2.9000	\$2.9000	\$2.9000
		MICs													\$7.0000	\$7.0000	\$7.0000		

Data shows the awarded price per dose (in US\$) per product per supplier per calendar year, based on a multi year supply agreement/LTA.

\*The \$ 7.00 price consists of a co-payment of a maximum of \$3.30/dose (the Tail Price) funded by a country or Gavi and a subsidy up to \$5.00/dose funded by the donors of the Advance Market Commitment (AMC).

\*Prices are based on a 10 year supply commitment and a volume guarantee as well as other terms as defined in the AMC legal framework .

(<http://www.gavialliance.org/funding/pneumococcal-amc/amc-legal-agreements/>).

\*Prices apply to Gavi-eligible and transitioning countries as listed on Gavi's website at <http://www.gavialliance.org/support/who/eligible/index.php> and <http://www.gavialliance.org/support/apply/graduating-countries/>

Prices displayed are in response to tenders with FCA incoterms, covering vaccines with VVMs.

Last updated 25th April 2023